CrossFAST Integrated Microcatheter Advanced Delivery System
Vantis Vascular, Inc. · Decision date Sep 18, 2026
What did the FDA decide?
Vantis Vascular, Inc. received a substantially equivalent (SESE) determination for the CrossFAST Integrated Microcatheter Advanced Delivery System under 510(k) K262817, dated September 18, 2026, with the submission received August 7, 2026. The device is a Class II percutaneous catheter under 21 CFR 870.1250, product code DQY, in the cardiovascular specialty. The FDA letter states the indications for use: access to discrete regions of the coronary and/or peripheral vasculature in conjunction with guide catheters, and placement of interventional devices.
SESE means the device may be marketed subject to general controls; it is not a PMA approval. The letter notes that a substantial equivalence determination does not establish compliance with other requirements of the Act, and it points to QMSR obligations and change-notification guidance. The public documentation does not include the predicate device identity, the summary of technological characteristics, or performance testing, so the basis for the equivalence finding is not described here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 18, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262817
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Vantis Vascular, Inc.
- Product code
- DQY
- Decision code
- SESE
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Percutaneous.
- Applicant
- Vantis Vascular, Inc.
- Product code
- DQY
- FDA device class
- 2
FDA decision timeline
K262817 received
Application receipt date recorded by FDA.
K262817 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vantis Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- San Jose, CA
Sources and methodology
- Original FDA record: K262817
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records